Skip to main content
. 2021 Feb 20;6(9):2841–2853. doi: 10.1016/j.bioactmat.2021.02.007

Fig. 5.

Fig. 5

Diabetic wound closure after treatment with engineered miR-31 exosomes. (A) General observation of diabetic wounds under different conditions; (B) healing rate of diabetic wounds under different conditions; *significant difference compared with high-dose engineered miR-31 exosomes (p < 0.05); **significant difference compared with high-dose engineered miR-31 exosomes (p < 0.01); ***significant difference compared with high-dose engineered miR-31 exosomes (p < 0.001); ****significant difference compared with high-dose engineered miR-31 exosomes (p < 0.0001).